10-Apr-2026
Analysts Are Bullish on These Healthcare Stocks: CVS Health (CVS), Crispr Therapeutics AG (CRSP)
TipRanks (Tue, 7-Apr 10:21 AM ET)
Quest Diagnostics to Release First Quarter Financial Results on April 21, 2026
PRNewswire (Thu, 19-Mar 10:00 AM ET)
PRNewswire (Thu, 12-Mar 4:07 PM ET)
Quest Diagnostics Introduces AI Companion to Help Patients Understand and Act on Lab Test Results
PRNewswire (Mon, 2-Mar 9:02 AM ET)
Quest Diagnostics Names Benjamin Beauvalot Senior Vice President, Chief Strategy and M&A Officer
PRNewswire (Thu, 26-Feb 8:25 AM ET)
Quest Diagnostics to Speak at the Leerink 2026 Global Healthcare Conference
PRNewswire (Wed, 25-Feb 10:00 AM ET)
Market Chameleon (Tue, 10-Feb 2:40 AM ET)
PRNewswire (Tue, 10-Feb 6:47 AM ET)
PRNewswire (Tue, 10-Feb 6:33 AM ET)
PRNewswire (Mon, 2-Feb 8:52 AM ET)
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Quest Diagnostics trades on the NYSE stock market under the symbol DGX.
As of April 10, 2026, DGX stock price declined to $191.51 with 994,772 million shares trading.
DGX has a beta of 0.10, meaning it tends to be less sensitive to market movements. DGX has a correlation of 0.00 to the broad based SPY ETF.
DGX has a market cap of $21.30 billion. This is considered a Large Cap stock.
Last quarter Quest Diagnostics reported $3 billion in Revenue and $2.42 earnings per share. This beat revenue expectation by $49 million and exceeded earnings estimates by $.07.
In the last 3 years, DGX traded as high as $213.50 and as low as $119.59.
The top ETF exchange traded funds that DGX belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
DGX has underperformed the market in the last year with a price return of +18.9% while the SPY ETF gained +30.9%. However, in the short term, DGX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +10.7% vs -1.8% return in SPY. But in the last 2 weeks, DGX shares have been beat by the market, returning -1.6% compared to an SPY return of +7.2%.
DGX support price is $195.42 and resistance is $200.22 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DGX shares will trade within this expected range on the day.